Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 0.81% 124.00 35,839 14:19:54
Bid Price Offer Price High Price Low Price Open Price
122.00 126.00 124.00 122.00 123.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.44 0.50 0.62 200.0 104
Last Trade Time Trade Type Trade Size Trade Price Currency
14:19:29 O 6,000 125.00 GBX

Diaceutics (DXRX) Latest News (1)

More Diaceutics News
Diaceutics Investors    Diaceutics Takeover Rumours

Diaceutics (DXRX) Discussions and Chat

Diaceutics Forums and Chat

Date Time Title Posts

Add a New Thread

Diaceutics (DXRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Diaceutics trades in real-time

Diaceutics (DXRX) Top Chat Posts

Diaceutics Daily Update: Diaceutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DXRX. The last closing price for Diaceutics was 123p.
Diaceutics Plc has a 4 week average price of 122p and a 12 week average price of 113.50p.
The 1 year high share price is 191p while the 1 year low share price is currently 107p.
There are currently 84,068,923 shares in issue and the average daily traded volume is 5,633 shares. The market capitalisation of Diaceutics Plc is £104,245,464.52.
74tom: It depends on your definition of 'soon', the price was £1 at the start of the year and they've since added 14m shares @ £1.45.. They had a clean slate from the IPO until today, now sentiment is negative we'll see the low free float work against them, in the same way it drove the price up in January. They IPO'd at 76p and it honestly wouldn't surprise me to see the price back down at those levels before any turnaround, so potentially another 40% downside at least.
74tom: Always a dangerous game to buy ahead of interims and trying to second guess the outlook statement. Hopefully nobody followed the punt by netcurtains, or they'll be nursing a 20% loss in a mega illiquid share. They did very well to get £30m away at £1.45 over the summer, but their market cap is very heavy if existing revenues are now in decline & it's unclear when their unproven platform will start generating revenue...
gizmohican: Share price shooting up must be a trading update coming soon, looking at when last years was released!
cyberbub: Not only should that new money see them through till the end of 2021, but it appears that people have invested heavily, at a very small discount, in a company on a forward p/e of probably about 50.The only way I can explain it is if investors believe that the new 'Nexus' platform will really deliver a major step change in revenue... leading to a leveraged rocket in net profit, due to large central costs which may not increase that much. With a very high 77% gross profit margin, it does seem credible??If you consider Slater's PEG ratio, it's on a p/e of 50 now, but if profits were to grow at a (say) 100% rate for the next few years, it would be considered very good value on a PEG of 0.5.If DXRX capture say 25% of the medium-term $2bn global testing market = $500m, at say 70% margin = $350m = say conservatively £150m after tax. Nice recurring revenues usually get a p/e of 15 so the company could be on a £2.5bn market cap, or a 25-bagger from today.So... Can anyone who knows the market better then me explain why DXRX's offering is so good that (a) they can make 77% gross margin, and (b) they don't need to worry too much about competition and can capture a big chunk of the market?Thanks!NAI
tomps2: DXRX presentation at ShareSoc London, February 20202 by CEO, Peter Keeling Https://
woodcutter: The reason why there's probaly so little interest is it looks like another massively over priced ipo from what i can see in the admission document. Revenue for 2018 was £10.4. a 40% increase on 2017. operating profit was £1.2m operating margin 11.5% decent but nothing special. If they grow sales next year at 40% again then revenue is £14.6m assuming a similar margin then operating profit will be around 1.7m again assuming no debt after the ipo and ignoring tax and D&A £1.7m equates to around 2.5p/share at an operation level (67m shares) my best guess would be it will deliver eps less than 2p all told. If it gets to half the current share price it may attract my attention. woody
Diaceutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210308 15:34:30